Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · IEX Real-Time Price · USD
14.17
-0.18 (-1.25%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Entrada Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Net Income
-6.69-94.62-51.16-26.52-5.1
Depreciation & Amortization
2.841.91.120.330.1
Share-Based Compensation
13.119.92.530.330.29
Other Operating Activities
130.54-10.96-3.350.3-6.1
Operating Cash Flow
139.8-93.79-50.86-25.57-10.8
Capital Expenditures
-5.61-2.89-4.58-2.32-0.63
Change in Investments
-132.78-145.76000
Investing Cash Flow
-138.4-148.65-4.58-2.32-0.63
Share Issuance / Repurchase
21.040.48191.630.250.04
Other Financing Activities
--115.8349.84-
Financing Cash Flow
21.040.48307.4650.090.04
Net Cash Flow
22.45-241.96252.0222.2-11.39
Free Cash Flow
134.19-96.67-55.44-27.89-11.43
Free Cash Flow Margin
104.01%----
Free Cash Flow Per Share
4.06-3.09-8.85-25.23-1.69
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).